On Wednesday, GSK GSK.L exceeded expectations for profit and sales in the fourth quarter thanks to sales of its wildly popular shingles vaccination Shingrix.
The London-listed pharmaceutical company, which last July spun off its consumer health division after years of planning, declared an adjusted profit of 25.8 pence per share on sales of almost 7.4 billion pounds ($9.11 billion).
According to company-compiled consensus forecasts, analysts were expecting 21.2 pence per share on sales of approximately 7.1 billion pounds.
GSK, which is now entirely focused on vaccines and medications, also projected that in 2023, excluding any contributions from the company’s COVID-19 solutions business, sales would rise by 6% to 8% and adjusted operating profit would increase by 10% to 12%.
Over the quarter, Shingrix generated 769 million pounds, exceeding the 748 million in the GSK-compiled consensus projections.
(1 dollar = 0.8120 pounds)